Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Sponsor: University of Colorado, Denver
Summary
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
Official title: Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2025-03-06
Completion Date
2029-06-30
Last Updated
2025-05-06
Healthy Volunteers
No
Interventions
Tirzepatide
Titrated to dose of 5 mg once weekly subcutaneous
Placebo
Titrated to dose of 5 mg once weekly subcutaneous
Locations (1)
University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States